Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:07:15 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ARWR - ARROWHEAD PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ARWR - Q2.060.30·64.959.964.52-0.12-0.224,090.61,555,23546,59765.50  68.44  63.4676.76  9.5719:23:50Feb 0515 min RT 2¢

Recent Trades - Last 10 of 46597
Time ETExPriceChangeVolume
19:23:50Q64.680.043
18:33:25Q64.71210.072150
18:19:50Q64.56-0.0840
17:50:40Q64.860.2210
17:43:39Q64.860.2220
17:43:06Q64.52-0.12165,613
17:37:49Q64.56-0.0815
17:37:27Q64.52-0.12235,214
17:33:03Q64.950.3150
16:54:05Q64.950.31100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-05 16:05U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
2026-02-04 18:15U:ARWRNews ReleaseCiena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
2026-01-27 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
2026-01-20 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
2026-01-07 23:05U:ARWRNews ReleaseArrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
2026-01-07 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO(TM) (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
2026-01-06 18:14U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
2026-01-06 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
2026-01-05 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO(TM) (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
2025-12-23 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
2025-12-15 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-12-08 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
2025-12-02 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
2025-12-01 16:00U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
2025-11-25 16:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
2025-11-24 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
2025-11-18 11:52U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO(TM) (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
2025-11-06 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
2025-11-04 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
2025-10-28 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)